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ABSTRACT: A novel synthetic pathway for trifluoromethylthioferrocene (3), which does not involve the use of toxic mercury(II)-
based reagents, is described. The novel approach involves first the treatment of the commercially available bromoferrocene (1a) 
with NaSCN in the presence of copper(+I) to yield thiocyanatoferrocene (1), and then the reaction of 1 with the Rupper-Prakash 
reagent and tetrabutylammonium fluoride (TBAF) to give 3 in an overall yield of 60%. This approach could be extended for the 
preparation of thiocyanato-(4) and trifluoromethylthio-ruthenocene (7), which are herein both reported for the first time. Interest-
ingly, diferrocenyl disulfide (2a) and diruthenocenyl disulfide (5) could be isolated as side-products during the synthesis of 3 and 7, 
respectively. All new compounds were unambiguously characterized by 1H, 13C and 19F NMR spectroscopy, mass spectrometry, 
cyclic voltammetry, elemental analysis as well by X-ray crystallography for 1, 4, 4b, 5, 6 and 7. 1-7 were then tested for their toxic 
activity on a cervical cancer (HeLa) and on a non-cancerous (MRC-5) cell lines. All organometallic compounds were found to be 
either not toxic or to have a moderate toxicity towards the cell lines used in this study. 
INTRODUCTION  
Fluorinated compounds are playing a pivotal role in modern 
drug design. Several blockbuster drugs such as the anticancer 
drug 5-fluorouracil or the antidepressant drug Fluoxetine 
(Prozac®) bear one or several fluorine atom(s).1-3 In fact, 20-
25% of the drugs in the pharmaceutical pipeline contain a 
fluorine atom.3 This number is even more impressive if we 
take into account that organofluorine compounds are not pre-
sent in natural products.3  
Over the recent years, the trifluoromethylthio group (-SCF3) 
has become a privileged pharmacophore in many agrochemi-
cal and pharmaceutical compounds notably due to its extreme-
ly high lipophilicity. The antiparasitic drug Toltrazuril and 
insecticide Fipronil are two successful examples of this class 
of compounds.4-7 Lipophilicity is often crucial for drug uptake 
and intracellular accumulation and can therefore decide on the 
bioactivity of a drug molecule.3 An impressive number of 
procedures and reagents have been recently reported to intro-
duce an S-CF3 group into various molecules.4,7-9 However, the 
currently available publications in this field are mainly focus-
ing on purely organic compounds. The number of reports 
describing the preparation of S-CF3-containing and more 
generally of fluorine-containing organometallic complexes is 
indeed relatively scarce.10-17 This is rather surprising since, 
over the recent years, organometallic compounds, and espe-
cially ferrocenyl derivatives,18,19 were shown to hold great 
promises as antimalarial,20 antibacterial21 or anticancer22 
agents.23-26 Of special synthetic interest is a recent article of 
Metzler-Nolte et al. describing the synthesis of 
trifluoromethylthioferrocene (3, Scheme 1).12 In this work, the 
authors successfully prepared 3 in good yield starting from 
bromoferrocene (1a) by nucleophilic substitution of the bromo 
group with SCF3- using Hg(SCF3)2 and copper bronze (Scheme 
1).12 Unfortunately, this procedure depends on a mercury(+II) 
based reagent, which is highly toxic and commercially availa-
ble limited.27 Taking into consideration the potential of fluo-
rine-containing organometallic compounds, our group decided 
to explore an alternative approach, using less toxic reagents 
and mild conditions, to prepare not only 3 but also its heavier 
congener, trifluoromethylthioruthenocene (7). In this article, 
we describe the successful preparation of 3 and 7. In addition, 
the toxic profile of all compounds synthesized in this work (1-
7) on the cervical cancer (HeLa) and on the non-cancerous 
(MRC-5) cell lines is also reported. Furthermore, the electro-
chemical behavior of 1, 1a, 2a and 3 is also described to eval-
uate the influence of the different electron-withdrawing sub-
stituent on the reduction potentials of the ferrocenyl moieties 
present in 1-3.  
 
Scheme 1. Synthetic Procedure for 3 described by Metzler-
Nolte et al.12 
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Conditions: (i) Hg(SCF3)2/Cu, hexane, reflux, overnight, 82%. 
 
RESULTS AND DISCUSSION  
Syntheses and characterization. The synthetic pathway used 
in our study to prepare 3 is outlined in Scheme 2. In a first 
 attempt, we aimed to synthesize 3 in a single reaction step by 
applying a modified procedure reported by Chen et al.,28 
namely by treatment of 1a with S8, copper(I) iodide and me-
thyl fluorosulfonyldifluoroacetate in N-methylpyrrolidinone 
(NMP) at 100 °C overnight. These conditions only led to the 
formation of trace amounts of 3.  However, when the commer-
cially available bromoferrocene (1a) was refluxed in the pres-
ence of sodium thiocyanate and catalytic amounts of Cu2O, 
thiocyanatoferrocene (1) could be obtained as an orange solid 
in 67% yield.29,30 In addition to the unreacted bromoferrocene, 
which could be recovered, the major side-product of this reac-
tion is the literature-known diferrocenyl disulfide (2a). 
Cyanoferrocene (2b) could also be found in trace amounts as a 
minor side-product.31 The desired compound 3 was obtained 
by treating 1 with an excess of the commercially available 
Ruppert-Prakash reagent (Me3SiCF3) and a catalytic amount of 
a tetrabutylammonium fluoride solution in THF using slightly 
different conditions to those reported by Langlois et al.32-34 3 
was obtained as a yellow oil in excellent yield (90%) and the 
spectroscopic data matched those previously described by 
Metzler-Nolte et al.12 
 
Scheme 2. Synthetic Pathway for 3 
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Conditions: (i) NaSCN, Cu2O, dry MeCN, 64 h, reflux; 67%. (ii) 
Me3SiCF3, TBAF (THF soln. 1 M), dry THF, 10 min, -10 °C, 
90%.  
Encouraged by the promising results obtained for 3 and the 
importance of small functionalized metallocenes,35 we decided 
to investigate the possibility to prepare ruthenocenyl ana-
logues of 1 and 3. Of note, ruthenocene derivatives were 
shown, over the last years, to have interesting biological prop-
erties and to be an interesting surrogate for ferrocenyl deriva-
tives to understand the mechanism of action of these 
ferrocenyl compounds.36-40 The synthetic sequence to obtain 
the desired ruthenocene analogue 
trifluoromethylthioruthenocene (7) is outlined in Scheme 3. A 
mixture of mono- and diiodoruthenocene (4a/4b) was pre-
pared according to a literature procedure and then refluxed in a 
similar fashion to 1a with an excess of NaSCN and a catalytic 
amount of Cu2O.41 Thiocyanatoruthenocene (4) was isolated as 
a colorless solid as the major product in 89% yield in addition 
to 1-1`-thiocyanatoiodoruthenocene (6) and diruthenocenyl 
disulfide (5) in 20% and 4% yields, respectively. The for-
mation of 4, 5 and 6 was confirmed by EI-MS with peaks at 
m/z = 288, 263 and 415 corresponding to [M+], [M- 
C10H9SRu]+ and [M+], respectively. Interestingly, the for-
mation of a bis-substituted ruthenocenyl analogue, namely 
dithiocyanatoruthenocene, was never observed during our 
trials to obtain 4. In the last reaction step, 4 was reacted with 
an excess of the Rupper-Prakash reagent and a catalytic 
amount of TBAF in THF at -10°C to afford 7 in excellent 
yield (77%). The presence of 7 was ascertained by 1H spec-
troscopy with the characteristic peak pattern at 4.85-4.84, 
4.72-4.71 and 4.62 ppm, corresponding to the protons of the 
ruthenocenyl unit. Furthermore, only one single peak could be 
observed in 19F NMR spectroscopy at -46.3 ppm that can be 
attributed to the SCF3 group. 
 
Scheme 3. Synthetic Pathway for 7 
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Conditions: (i) NaSCN, Cu2O, dry MeCN, 64 h, reflux; 89%. 
(ii) Me3SiCF3, TBAF (THF soln. 1 M), dry THF, 10 min, -10 
°C, 77%. 
 
X-ray crystallography. Single crystals of 1, 4, 4b, 5, 6 and 7 
suitable for X-ray crystallography analysis could be grown by 
slow evaporation of the corresponding solutions of 1, 4, 4b, 5, 
6 and 7 in chloroform. The ORTEP plots of 1 and 7 are shown 
in Figure 1 and those of 4, 4b, 5 and 6 in Figures S14 – S17 
(see SI). All additional crystallographic information are pre-
sented in the SI. 1 crystallized in the orthorhombic space 
group Pnma and measurements indicate classical bond angles 
and distances for such types of bonds.42-44 4 is essentially 
isostructural to 1 with the same space group Pnma and a 
slightly bigger cell. In both cases, the complexes display Cs 
symmetry that is shared with the mirror plane of the space 
group. 5 is not crystallizing in the same space group (P21) as 
the already published X-ray structure of 2a.45 
 
Figure 1. Molecular structure of 1 and 7 with atoms shown as 
thermal ellipsoids (drawn at 50% probability, hydrogen atoms 
are omitted for clarity). 
Fe1
1 7  
Ru1 
 Electrochemical studies. Voltammetric studies on com-
pounds 1, 1a, 2a and 3 at 1 mM concentrations in CH3CN 
were carried out in order to investigate the influence of differ-
ent substituted cyclopentadienyl rings on the oxida-
tion/reduction of the ferrocene redox couple. For this purpose, 
a stationary glassy carbon (GC) electrode was used to perform 
the cyclic voltammetry with a scan rate of 100 mVs-1 in 
CH3CN with tetrabutylammonium hexafluorophosphate 
(Bu4NPF6, 0.1 M) as the supporting electrolyte. A Pt electrode 
was used as the working electrode and Ag/AgCl as the refer-
ence electrode. As an internal reference, decamethylferrocene 
(DMFc, 0.25 mM) was used instead of the usual ferrocene in 
order to avoid overlaps of the studied compounds with the 
ferrocene oxidation process. The cyclic voltammogram of 1a, 
1, 2a and 3 are presented in the SI and the results are summa-
rized in Table 1. 
Table 1 – Cyclic Voltammetric Data for 1a, 1, 2a, 3 in the 
presence of an internal reference (DMFc) at a GC Electrode in 
CH3CN/Bu4NPF6 (0.1 M) with a scan rate of 100 mVs-1.  
Compound E
0
f vs DMFc0/+ 
[mV] Ep [mV] 
1a +674 80 
1 +802 89 
2a +615 
+779 
90 
79   
3 +804 89 
Oxidation peak potential = Epox; reduction peak potential = 
Epred; formal redox potential E0f = (Epox + Epred)/2.  
All oxidation potentials are assigned to the reversible oxida-
tion/reduction of the ferrocene redox couple and are in the 
expected range. 1a, 1 and 3 show one reversible single oxida-
tion wave, while 2a has two reversible oxidation waves, one at 
+615 mV and the other at slightly higher potential +784 mV. 
The stronger electron withdrawing effect of the SCN- and 
SCF3- group vs the Br- functionality is clearly visible in the 
higher oxidation potential of 1 and 3 (+802 mV and +804 mV) 
compared to 1a (+674 mV). 
 
Cytotoxicity studies. With the metallocene derivatives 1-7 in 
hand, we then investigated their toxicity towards the cervical 
cancer (HeLa) and the non-cancerous (MRC-5) cell lines. 
Cisplatin was used as reference compound. As can be seen in 
Table 2, the seven organometallic compounds showed either 
moderate cytotoxicity in the range of 29.0 - 61.2 µM or even 
no toxicity at all towards HeLa cells.   
 
CONCLUSION 
In summary, we present herein an efficient synthetic pathway 
for thiocyanato- and trifluoromethylthio- ferrocene and 
ruthenocene. Importantly, the synthetic route employed to-
wards the trifluoromethylthio-metallocenes does not rely on a 
highly toxic and commercially available limited mercury(+II) 
salt. In addition, the crystallographic data of six organometal-
lic compounds are reported. We could also demonstrate that 
all organometallic complexes prepared in this work had either 
modest or even no toxic activity on a cervical cancer (HeLa) 
and on a non-cancerous (MRC-5) cell line. We are confident 
that the synthetic conditions reported in this article will enable 
the formation of higher substituted metallocenes with interest-
ing biological properties.  
 
Table 2 - Cytotoxicity activity (IC50) of 1-7 against HeLa and 
MRC-5 cells. 
Compound 
IC50 values (M) 
HeLa MRC-5 
 
1a          
1 
 
> 100 
38.5  3.3 
 
> 100 
48.5  1.0 
2a > 100 > 100 
3 > 100 >100 
4 61.2  3.3 47.2  7.5 
5 38.7  7.4 57.4  10.9 
6 
7 
29.0  1.9 
> 100 
25.2  4.1 
> 100  
Cisplatin 9.6  1.2 17.6  4.3 
 
EXPERIMENTAL PART 
Materials. All chemicals were of reagent grade quality or 
better, obtained from commercial suppliers and used without 
further purification. Solvents were used as received or distilled 
using standard procedures.46 All preparations were carried out 
using standard Schlenk techniques and all reac-
tions/compounds were protected from light as much as possi-
ble using aluminium foil. Thin layer chromatography (TLC) 
was performed using silica gel 60 F-254 (Merck) plates with 
detection of spots being achieved by exposure to UV light. 
Column chromatography was performed using Silica gel 60 
(0.040-0.063 mm mesh, Merck). Eluent mixtures are ex-
pressed as volume to volume (v/v) ratios. Ruthenocene was 
synthesized according to a literature procedure.47  
Instrumentation and methods. 1H, 13C and 19F NMR spectra 
were recorded in deuterated solvents on Bruker AV2-401, 
AV2-400, AV-500, AV-501 and DRX-500 spectrometers, at 
room temperature. The chemical shifts, δ, are reported in ppm 
(parts per million). The signals from the residual protons of 
deuterated solvent have been used as an internal reference.48,49 
The abbreviations for the peak multiplicities are as follows: s 
(singlet), d (doublet), dd (doublet of doublets), t (triplet), q 
(quartet), m (multiplet), and br (broad). ESI mass spectrometry 
was performed using a Bruker Esquire 6000 spectrometer. In 
the assignment of the mass spectra, the most intense peak is 
listed. Cyclic voltammetric measurements were performed at 
room temperature in acetonitrile solutions containing 0.1 M 
tetrabutyl ammonium hexafluorophosphate as the supporting 
electrolyte with a scan rate of 100 mVs−1 using a Methrom 
757 VA Computrace electrochemical workstation. Solutions 
used in electrochemical measurements were deoxygenated by 
purging with nitrogen for at least 10 min before commencing 
the experiments. A conventional three electrode cell was em-
ployed which comprised a glassy carbon working electrode, a 
large surface area Pt counter electrode and an Ag/AgCl refer-
ence electrode. EI-MS: Mass spectrometry was performed on 
a Thermo DFS (ThermoFisher Scientific, Bremen, Germany) 
double-focusing magnetic sector mass spectrometer (geometry 
BE). Mass spectra were measured in electron impact (EI) 
mode at 70 eV, with solid probe inlet, source temperature of 
 200 °C, acceleration voltage of 5 kV, and resolution of 2’500. 
The instrument was scanned between m/z 30 and 900 at scan 
rate of 2 s / decade in the magnetic scan mode. Perfluorokero-
sene (PFK, Fluorochem, Derbyshire, UK) served for calibra-
tion. HR-EI-MS: High-resolution mass spectrometry was 
performed on a Thermo DFS (ThermoFisher Scientific, Bre-
men, Germany) double-focusing magnetic sector mass spec-
trometer (geometry BE). Mass spectra were measured in elec-
tron impact (EI) mode at 45 eV, with solid probe inlet, a 
source temperature of 200 °C, an acceleration voltage of 5 kV, 
and a resolution of 10’000. The instrument was scanned be-
tween e.g. m/z 300 und 350 at scan rate of 100-200 s / decade 
in the electric scan mode. Perfluorokerosene (PFK, Fluoro-
chem, Derbyshire, UK) served for calibration. Infrared spectra 
were recorded on Perkin-Elmer FTIR spectrometer fitted with 
an ATR platform. Peak intensities are given as broad (b), very 
strong (vs), strong (s), medium (m) and weak (w). 
Synthesis. Thiocyanatoferrocene (1) and diferrocenyl disul-
fide (2a). 1 was synthesized by refluxing bromoferrocene (1a, 
500 mg, 1.90 mmol) in dry acetonitrile (65 mL), together with 
sodium thiocyanate (1.15 g, 14.22 mmol) in the presence of a 
catalytic amount of Cu2O (0.07 g, 0.47 mmol) for 64 h. The 
reaction mixture was then allowed to reach room temperature, 
filtered and the solvent was removed in vacuo. The beige to 
orange crude solid was purified by column chromatography on 
silica using hexane:ethyl acetate (25:1) as eluent to give 1 
(Rf = 0.35) as an orange solid and 2a (Rf = 0.46) as bright 
orange crystals, respectively. Yields: 1: 0.30 g (67%, 1.25 
mmol); 2a: 0.06 g (7.5%, 0.14 mmol). Spectroscopic data for 
1 and 2a matched those previously reported by Knox et al.30 
and Herberhold et al.,50 respectively. To confirm the purity of 
1 and 2a for biological experiments, microanalysis and HR EI-
MS were performed. Elemental Analysis for 1: calcd. for 
C11H9FeNS = C, 54.35; H, 3.73; N, 5.76. Found = C, 54.39; H, 
3.58; N, 5.10. HR EI-MS of 1: calcd. for C11H9FeNS (M+) m/z 
(%) = 242.97996. Found m/z (%) = 242.97994. Elemental 
Analysis for 2a: calcd. for C20H18Fe2S2: C, 55.30; H, 4.18. 
Found: C, 55.51; H, 4.12. HR EI-MS for 2a: calcd. for 
C20H18Fe2S2 (M+) m/z (%) = 433.95432. Found m/z (%) = 
433.95484. 
Trifluoromethylthioferrocene (3). 1 (0.05 g, 0.21 mmol) was 
dissolved in dry THF (50 mL), then degassed for 30 min and 
cooled to -10 °C. An excess of trifluoromethyltrimethylsilane 
(0.47 mL, 3.15 mmol) was then added to this yellow reaction 
solution. The temperature of the reaction mixture was main-
tained at -10 °C while a catalytic amount of 
tetrabutylammoniumfluoride solution (1 M in THF, 0.09 mL, 
0.09 mmol) was added dropwise to the solution containing 
trifluoromethyltrimethylsilane and 1 over a period of 10 min. 
The reaction solution was further stirred for 5 min and then 
directly filtered through a silica plug. The product was further 
eluted from the plug by dichloromethane. Based on the ob-
served volatility of 3 at low pressure and elevated temperature, 
the solution was dried by a gentle stream of N2 gas to obtain 
the orange oily product 3. Yield: 0.054 g (90%, 0.19 mmol). 
Spectroscopic data matched those previously reported by 
Metzler-Nolte et al.12 To confirm the purity of 3 for the bio-
logical experiments, microanalysis and HR EI-MS were per-
formed. Elemental Analysis for 3: calcd. For C11H9F3SFe: C, 
46.18; H, 3.17. Found: C, 46.36; H, 3.34. HR EI-MS of 3: 
calcd. for C11H9F3FeS (M+) m/z (%) = 285.97210. Found m/z 
(%) = 285.97213. 
 
Monoiodoruthenocene (4a) and Diiodoruthenocene (4b). The 
synthesis was carried out according to a modified literature 
procedure.41 Ruthenocene (0.565 g, 2.44 mmol) and KOtBu 
(0.034 g, 0.303 mmol) were first dissolved in dry THF (40 
mL) and the solution was cooled to -78 °C. To this solution 
was added a 1.9 M solution of t-BuLi in pentane (2.6 mL, 4.94 
mmol) over a period of 30 min while maintaining the tempera-
ture at -78 °C. After stirring for 30 min at -78 °C, a solution of 
I2 (1.55 g, 6.11 mmol) in dry THF (20 mL) was added slowly 
to the reaction mixture at the same temperature. The reaction 
mixture was left to reach room temperature, further stirred for 
24 h and then concentrated under reduced pressure. The crude 
product was purified by column chromatography on silica, 
using hexane as eluent, to give 4a (Rf = 0.44) and 4b (Rf = 
0.45) as light yellow solids. Yield: 4a: 0.432 g (49%); 4b: 
0.188 g (16%). The characterization data for 4a and 4b 
matched those previously reported.41  
Thiocyanatoruthenocene (4), diruthenocenyl disulfide (5) and 
1-1`-thiocyanatoiodoruthenocene (6). 4 was synthesized ac-
cording to the procedure described for 1. A mixture of 
monoruthenocene (4a, 0.17 g, 0.47 mmol) and 
diiodoruthenocene (4b, 0.06 g, 0.12 mmol) was refluxed in 
dry acetonitrile (40 mL) with an excess of sodium thiocyanate 
(0.39 g, 4.83 mmol) and a catalytic amount of Cu2O (0.01 g, 
0.05 mmol) for 64 h. The reaction was then allowed to reach 
room temperature, filtered and evaporated in vacuo. The crude 
colorless solid was purified by column chromatography on 
silica using hexane:ethyl acetate (30:1) as eluent. 4 (Rf = 0.24, 
hexane:ethylacetate (25:1)) was obtained as colorless solid. 
Yield: 0.12 g (89%, 0.42 mmol). 5 (Rf = 0.36, hex-
ane:ethylacetate (25:1)) and 6 (Rf = 0.15, hexane:ethylacetate 
(25:1)) could be also isolated as colorless solids. Yield 5: 0.01 
g (4%, 0.019 mmol). Yield 6: 0.01 g (20%, 0.024 mmol).  
Data for 4: IR (Golden Gate, cm-1): 3104, 2923, 2154, 1791, 
1744, 1709, 1663, 1639, 1409, 1400, 1386, 1346, 1157, 1102, 
1019, 1014, 999, 883, 843, 824, 812, 722. 1H NMR (400 MHz, 
CDCl3): δ/ppm = 4.92-4.91 (m, 2H, C5H4), 4.71-4.69 (m, 2H, 
C5H4), 4.65 (s, 5H, C5H5). 13C NMR (125 MHz, CDCl3): δ/ppm = 113.0, 75.9, 73.1, 72.8, 70.9.  EI-MS: m/z (%) = 
287.9 ([M+], 100), 262.9 ([M-CN]+, 26) 198.9 ([M-C6H4N] +, 
13), 166.9 ([M-C6H4SN] +, 24). HR EI-MS: calcd. for 
C11H9NRuS (M+) m/z (%) = 288.94937. Found m/z (%) = 
288.94911. Elemental Analysis: calcd. for C11H9NRuS: C, 
45.82; H, 3.15; N, 4.86. Found: C, 45.65; H, 3.07; N, 4.69. 
Data for 5: IR (Golden Gate, cm-1): 3104, 2962, 2929, 1799, 
1713, 1655, 1407, 1386, 1360, 1260, 1189, 1163, 1100, 1013, 
996, 886, 802, 708. 1H NMR (400 MHz, CDCl3): δ/ppm = 
4.75-4.74 (m, 4H, C5H4), 4.65-4.64 (m, 4H, C5H4), 4.56 (s, 
10H, C5H5).  13C NMR (125 MHz, CDCl3): δ/ppm = 84.2, 
76.3, 72.6, 72.0.  EI-MS: m/z (%) = 263.0 ([M-C10H9SRu] +, 
100). HR EI-MS: calcd. for C20H18Ru2S2 (M+) m/z (%) = 
525.89419. Found m/z (%) = 525.89314. Elemental Analysis: 
calcd. for C20H22O2Ru2S2: C, 42.85; H, 3.96. Found: C, 43.30; 
H, 4.35. 
Data for 6: IR (Golden Gate, cm-1): 3103, 2922, 2851, 2147, 
1685, 1399, 1375, 1357, 1337, 1260, 1162, 1138, 1051, 1027, 
1013, 1006, 915, 887, 866, 835, 820, 809, 727.  1H NMR (400 
MHz, CDCl3): δ/ppm = 4.94-4.93 (m, 1H, C5H4), 4.92-4.91 
(m, 1H, C5H4) 4.73-4.72 (m, 1H, C5H4), 4.57-4.56 (m, 1H, 
C5H4). 13C NMR (125 MHz, CDCl3): δ/ppm = 111.8, 79.8, 
 78.0, 75.5, 73.8, 72.1, 36.1. EI-MS: m/z (%) = 414.9 ([M+], 
100), 288.0 ([M-I]+, 78). HR EI-MS: calcd. for C11H8NIRuS 
(M+) m/z (%) = 414.84602. Found m/z (%) = 414.84617. Ele-
mental Analysis: calcd. for C11H8NIRuS: C, 31.89; H, 1.95; N, 
3.38. Found: C, 31.28; H, 1.92; N, 3.13. 
Trifluoromethylthioruthenocene (7). 7 was synthesized using a 
similar procedure to the preparation of 3. 4 (0.05 g, 0.17 
mmol) was dissolved in dry THF (50 mL) which was previ-
ously degassed for 30 min. The colorless reaction solution was 
strongly stirred and cooled to -10 °C. 
Trifluoromethyltrimethylsilane (0.37 mL, 2.55 mmol) was 
then added in excess to the reaction solution. A catalytic 
amount of tetrabutylammoniumfluoride solution (1 M in THF, 
0.073 mL, 0.073 mmol) was added dropwise over a period of 
10 min to the solution containing 
trifluoromethyltrimethylsilane and 4. The temperature of the 
reaction was maintained at -10 °C while adding the 
tetrabutylammoniumfluoride solution. After further stirring for 
5 min, the reaction was filtered through a silica plug. The 
product was further eluted with dichloromethane. Based on the 
observed volatility of 7 at low pressure and elevated tempera-
ture, the crude product was dried by a stream of N2 gas and 
further purified by a column chromatography on silica using 
hexane as eluent. 7 (Rf = 0.56) was obtained as colorless solid. 
Yield: 0.042 g (77%, 0.13 mmol). 
Data for 7: IR (Golden Gate, cm-1): 3087, 2924, 2851, 1671, 
1411, 1390, 1167, 1109, 1023, 1013, 995, 892, 866, 839, 824, 
809, 750, 723. 1H NMR (400 MHz, CDCl3): δ/ppm = 4.85-
4.84 (m, 2H, C5H4), 4.72-4.71 (m, 2H, C5H4), 4.62 (s, 5H, 
C5H5).  13C NMR (125 MHz, CDCl3): δ/ppm = 132.5, 130.0, 
127.5, 125.1, 77.8, 73.3, 72.3, 69.4.  19F NMR (400 MHz, 
CDCl3): δ/ppm = -46.3. EI-MS: m/z (%) = 332.0 ([M+], 36), 
263.0 ([M-CF3] +, 100). HR EI-MS: calcd. for C11H9F3RuS 
(M+) m/z (%) = 331.94151. Found m/z (%) = 331.94178. Ele-
mental Analysis: calcd. for C11H9F3RuS: C, 39.88; H, 2.74. 
Found: C, 40.01; H, 2.75. 
Crystallographic studies. Crystallographic data were col-
lected at 183(2) K on an Oxford Diffraction Xcalibur system 
with a Ruby detector using Mo Kα radiation (λ = 0.7107 Å) 
that was graphite-monochromated. Suitable crystals were 
covered with oil (Infineum V8512, formerly known as Para-
tone N), placed on a nylon loop that is mounted in a Crystal-
Cap Magnetic™ from Hampton Research and immediately 
transferred to the diffractometer. The program suite CrysAlis-
Pro was used for data collection, multi-scan absorption correc-
tion and data reduction.51 The structures were solved with 
direct methods using SIR9752 and were refined by full-matrix 
least-squares methods on F2 with SHELXL-97.53 The struc-
tures were checked for higher symmetry with help of the pro-
gram Platon.54 Crystal 4b contained 4 molecules in the asym-
metric unit and was non-merohedrally twinned by a 180° 
rotation around the following vector in reciprocal space (hkl): 
0 1 0. Both twin domains were integrated and merged into a 
hklf5 file. The twin ratio refined to 86.6 : 13.4. In the crystal 
structure of 5, one non-substituted cp ring was found to be 
disordered in a 56:44 ratio. 
Cell Culture. Human cervical carcinoma cells (HeLa) cells 
were cultured in DMEM (Gibco) supplemented with 5% fetal 
calf serum (FCS, Gibco), 100 U/ml penicillin, 100 g/ml 
streptomycin at 37 °C and 5% CO2. The normal human fetal 
lung fibroblast MRC-5 cell line was maintained in F-10 medi-
um (Gibco) supplemented with 10% FCS (Gibco), penicillin 
(100 U/ml), and streptomycin (100 g/ml). 
Cytotoxicity Studies. Cytotoxicity studies were performed on 
two different cell lines, namely HeLa, and MRC-5, by a 
fluorometric cell viability assay using Resazurin (Promocell 
GmbH). Briefly, one day before treatment, cells were seeded 
in triplicates in 96-well plates at a density of 4 x 103 cells/well 
for HeLa and 7 x 103 for MRC-5 in 100 l growth medium. 
Upon treating cells with increasing concentrations of Fc-PZQ 
derivatives for 48h, the medium was removed, and 100 l 
complete medium containing Resazurin (0.2 mg/ml final con-
centration) were added. After 4h of incubation at 37 oC, fluo-
rescence of the highly red fluorescent product Resorufin was 
quantified at 590 nm emission with 540 nm excitation wave-
length in a SpectraMax M5 microplate Reader. 
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Trifluoromethylthioferrocene and its higher homologue trifluoromethylthioruthenocene, which is reported for the first time, were 
prepared in a reaction sequence involving first the treatment of the respective halogeno-metallocenes with NaSCN in the presence 
  
7
of copper(+I) to yield the thiocyanato-metallocenes and then the reaction of the latter with the Rupper-Prakash reagent and 
tetrabutylammonium fluoride to give the expected organometallic compounds in good yields. Importantly, this synthetic procedure 
does not involve the use of mercury reagents. 
 
 
 
  
